Stage IIIA Breast Cancer AJCC v7
35
1
12
18
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
17 trials with published results (49%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
11.4%
4 terminated out of 35 trials
81.8%
-4.8% vs benchmark
20%
7 trials in Phase 3/4
94%
17 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 18 completed trials
Clinical Trials (35)
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Breast Cancer WEight Loss Study (BWEL Study)
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
The Role of Lifestyle Factors in Breast Cancer-Related Outcomes
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer